DxTerity Receives New York Authorization for Type 1 Interferon (IFN-1) Gene Signature Testing for Systemic Lupus Erythematosus Patients

LOS ANGELES, Sept. 16, 2022 /PRNewswire/ -- The DxTerity IFN-1 gene signature test is for patients with Systemic Lupus Erythematosus (SLE or lupus), a chronic autoimmune disease affecting up to 1 million patients in the US. IFN-1 gene signature testing represents the advancement of...

Click to view original post